Acer Therapeutics Inc (ACER) USD 0.01
Acer Therapeutics Inc. is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. The Company's pipeline includes four programs: ACER-001, EDSIVO, ACER-801 and ACER-2820. The ACER-001 (Sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). The EDSIVO (celiprolol) is a selective adrenergic modulator (SAM) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation. The ACER-801 (osanetant) is a non-peptide tachykinin NK3 receptor antagonist for the treatment of induced Vasomotor Symptoms (iVMS). The ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.